New Zealand approves pharmaceutical-grade MDMA for severe PTSD
New Zealand's national drug regulator, Medsafe, approved the prescription of pharmaceutical-grade MDMA for severe PTSD. The country is the second to approve such use after Australia. The approval is for prescriptions by two psychiatrists and does not yet confirm that the treatment has been delivered to patients.
Why it matters
This responds to the limited treatment options for severe PTSD by creating a regulated pathway for a new medical therapy.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news